Needham Reiterates Hold Rating on Globus Medical (GMED)

Canaccord Genuity Reiterates Buy Rating on Globus Medical (GMED)

Canaccord Genuity analyst William J. Plovanic reiterated a Buy rating and $101.00 price target on Globus Medical (NYSE: GMED).

The analyst comments "Our take: We believe that this acquisition is further evidence of GMED continuing to go on the offensive even as it integrates its sizable acquisition of NUVA. With over one year since the NUVA merger, we are impressed by the progress GMED has achieved and how it's remained... More

Jefferies Reiterates Buy Rating on Globus Medical (GMED)

Jefferies analyst Matthew Taylor reiterated a Buy rating and $105.00 price target on Globus Medical (NYSE: GMED)

The analyst comments "On 2.6.25, GMED announced plans to acquire NVRO (UNPF) for ~$250MM in equity value ~0.6x sales. Assuming a 2Q25 close, GMED forecasts ~20c in... More

BTIG on Globus Medical (GMED) Buying NVRO: 'The Market May Not Like It'

BTIG analyst Ryan Zimmerman reiterated a Buy rating and $91.00 price target on Globus Medical (NYSE: GMED).

The analyst comments "This morning, GMED announced a definitive agreement to acquire Nevro Corp (NVRO, Not Rated) for ~$250M or ~0.6x EV/FY25 sales. Yes, this is surprising on the surface. We don't believe investors expected that GMED would move into... More

Stifel on Globus Medical (GMED) Buying NVRO: 'A Bit of a Head Scratcher'

Stifel analyst Mathew Blackman reiterated a Buy rating and $92.00 price target on Globus Medical (NYSE: GMED).

The analyst comments "In an unexpected move this morning, GMED announced the acquisition of NVRO for an equity value of ~$250M. Reflecting the impact of the transaction,... More

Globus Medical (GMED) to Acquire Nevro Corp. (NVRO)

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of... More

Dentsply Sirona (XRAY) appooints new board members

DENTSPLY SIRONA Inc. (Nasdaq: XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the Board), effective February 5, 2025.

Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the companys digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. Barber will be... More